Genelux (GNLX) Amortization - Deferred Charges (2023)
Genelux's (GNLX) quarterly Amortization - Deferred Charges came in at $108000.0 in Q1 2023.
Genelux (GNLX) Amortization - Deferred Charges (2023) Analysis & Trends
Genelux's Amortization - Deferred Charges history runs 1 years deep, the most recent figure standing at $108000.0 for Q1 2023.
- On a quarterly basis, Amortization - Deferred Charges changed N/A year-over-year to $108000.0 in Q1 2023; TTM through Dec 2023 was $108000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $108000.0, up 77.05% from the prior year.
- Amortization - Deferred Charges held at $108000.0 in Q1 2023 per GNLX's latest filing.
- Across five years, Amortization - Deferred Charges topped out at $108000.0 in Q1 2023 and bottomed at $108000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn | - |
| 10 | Genelux | 128.48 Mn | 128.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 108,000.00 |
| Mar 31, 2023 | 108,000.00 |